NCT02446847View on ClinicalTrials.gov

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 11, 2015

Primary Completion Date

March 25, 2017

Study Completion Date

March 25, 2017

Conditions
HIV-1 Infection
Interventions
DRUG

3BNC117

3BNC117 infusions

OTHER

ART Interruption

Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.

Trial Locations (1)

10065

The Rockefeller University, New York

All Listed Sponsors
lead

Rockefeller University

OTHER

NCT02446847 - 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption | Biotech Hunter | Biotech Hunter